PL417876A1 - Applications of the derivative of diamine-dicarboxylic acid as the L-15 and IL-2 biologic activity inhibitor - Google Patents
Applications of the derivative of diamine-dicarboxylic acid as the L-15 and IL-2 biologic activity inhibitorInfo
- Publication number
- PL417876A1 PL417876A1 PL417876A PL41787614A PL417876A1 PL 417876 A1 PL417876 A1 PL 417876A1 PL 417876 A PL417876 A PL 417876A PL 41787614 A PL41787614 A PL 41787614A PL 417876 A1 PL417876 A1 PL 417876A1
- Authority
- PL
- Poland
- Prior art keywords
- derivative
- diamine
- applications
- dicarboxylic acid
- biologic activity
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000004071 biological effect Effects 0.000 title 1
- GUAHWEGWZUYTDA-UHFFFAOYSA-N CC(CCCCCCC(C(C(O)=O)C(O)=O)N)N Chemical class CC(CCCCCCC(C(C(O)=O)C(O)=O)N)N GUAHWEGWZUYTDA-UHFFFAOYSA-N 0.000 abstract 2
- 102000003812 Interleukin-15 Human genes 0.000 abstract 2
- 208000004232 Enteritis Diseases 0.000 abstract 1
- 108090000172 Interleukin-15 Proteins 0.000 abstract 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000000389 T-cell leukemia Diseases 0.000 abstract 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000306 sarcoidosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ujawniono zastosowanie pochodnej kwasu 2,9-diaminodekanodikarboksylowego jako inhibitora receptorów dla IL-15 i IL-2 w leczeniu i zapobieganiu chorób, u podłoża których leży nadmierna produkcja interleukiny 15 i interleukiny 2. Przedmiotem zgłoszenia jest również preparat farmaceutyczny zawierający terapeutycznie skuteczną ilość pochodnej kwasu 2,9-diaminodekanodikarboksylowego jako substancję aktywną oraz farmaceutycznie dopuszczalne nośniki i/lub substancje pomocnicze, do stosowania w zapobieganiu lub leczeniu chorób takich jak reumatoidalne zapalenie stawów, łuszczyca, zapalenie jelit, sarkoidoza, białaczki T-komórkowe lub odrzucanie przeszczepów.The use of a 2,9-diaminodecanedicarboxylic acid derivative has been disclosed as an inhibitor of IL-15 and IL-2 receptors in the treatment and prevention of diseases which are the cause of excessive production of interleukin 15 and interleukin 2. The subject of the application is also a pharmaceutical preparation containing a therapeutically effective amount of the acid derivative 2,9-diaminodecanedicarboxylic acid as the active substance and pharmaceutically acceptable carriers and / or excipients for use in the prevention or treatment of diseases such as rheumatoid arthritis, psoriasis, enteritis, sarcoidosis, T-cell leukemia or transplant rejection.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL40550513A PL405505A1 (en) | 2013-09-30 | 2013-09-30 | Application of the diaminodicarboxylic acid derivative as inhibitor biological activity of IL-15 and IL-3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL417876A1 true PL417876A1 (en) | 2017-02-13 |
Family
ID=51947386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL40550513A PL405505A1 (en) | 2013-09-30 | 2013-09-30 | Application of the diaminodicarboxylic acid derivative as inhibitor biological activity of IL-15 and IL-3 |
| PL417876A PL417876A1 (en) | 2013-09-30 | 2014-09-29 | Applications of the derivative of diamine-dicarboxylic acid as the L-15 and IL-2 biologic activity inhibitor |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL40550513A PL405505A1 (en) | 2013-09-30 | 2013-09-30 | Application of the diaminodicarboxylic acid derivative as inhibitor biological activity of IL-15 and IL-3 |
Country Status (2)
| Country | Link |
|---|---|
| PL (2) | PL405505A1 (en) |
| WO (1) | WO2015044761A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL142536A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Carriers for therapeutic preparations for treatment of t-cell mediated diseases |
| CU23472A1 (en) | 2004-09-17 | 2009-12-17 | Ct Ingenieria Genetica Biotech | ANTAGONIST PEPTIDE OF INTERLEUCINE-15 |
| US7807699B2 (en) * | 2006-03-21 | 2010-10-05 | Joyant Pharmaceuticals, Inc. | Dimeric pyrrolidine amide-containing small molecule apoptosis promoters |
| CU23716A1 (en) | 2008-09-30 | 2011-10-05 | Ct Ingenieria Genetica Biotech | ANTAGONIST PEPTIDE OF THE ACTIVITY OF INTERLEUCINA-15 |
| JP5478082B2 (en) * | 2009-01-20 | 2014-04-23 | 株式会社山田養蜂場本社 | Interleukin-2 production inhibitor |
-
2013
- 2013-09-30 PL PL40550513A patent/PL405505A1/en unknown
-
2014
- 2014-09-29 WO PCT/IB2014/001939 patent/WO2015044761A1/en not_active Ceased
- 2014-09-29 PL PL417876A patent/PL417876A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015044761A1 (en) | 2015-04-02 |
| PL405505A1 (en) | 2015-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MY189761A (en) | Quinazoline derivatives used to treat hiv | |
| TR201904455T4 (en) | 1,2,4-triazoles and their uses as nuclear transport modulators. | |
| MX388457B (en) | IMIDAZOPIRAZINE INHIBITORS OF BRUTON'S TYROSINE KINASE. | |
| MX378435B (en) | Site specific dosing of a btk inhibitor | |
| UA124922C2 (en) | NUCLEAR TRANSPORT MODULATORS AND THEIR APPLICATIONS | |
| MX2016013529A (en) | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof. | |
| MX2015008957A (en) | Fluoro-[1,3]oxazines as bace1 inhibitors. | |
| MX381230B (en) | NOVEL 1,2,4-DISUBSUBSTITUTED TRIAZINE COMPOUND. | |
| MX392259B (en) | FUSED 6-5 RINGS AS C5a INHIBITORS | |
| MX385898B (en) | FUSION MOLECULES DERIVED FROM COLIX TOXIN FOR ORAL DELIVERY OF A BIOLOGICALLY ACTIVE LOAD. | |
| MX391392B (en) | 5-5 FUSED RINGS AS C5a INHIBITORS. | |
| EA201591541A1 (en) | BETA SECRETASE INHIBITORS 1 (BACE 1) | |
| CL2016000436A1 (en) | Method for the treatment of fibrotic disease | |
| GEAP202215599A (en) | Boron containing pde4 inhibitors | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| JOP20190262B1 (en) | Pyrazole magl inhibitors | |
| EA201792057A1 (en) | CONDENSED BICYCLIC HETEROYARIL DERIVATIVES WITH ACTIVITY OF PROHYLDROXYLASE INHIBITORS | |
| ZA201807446B (en) | Improved drug formulations | |
| EA201890906A1 (en) | DERIVATIVES OF CHINOXALINE AND PYRIDOPYRASINE AS PI3Kβ INHIBITORS | |
| JOP20170127A1 (en) | A combined formula consisting of three antiviral compounds | |
| PL417879A1 (en) | Applications of the derivative of 7-aminocephalosporanic acid as the L-15 and IL-2 biologic activity inhibitor | |
| PH12017501336B1 (en) | Preventive and/or therapeutic agent of immune disease | |
| PL417876A1 (en) | Applications of the derivative of diamine-dicarboxylic acid as the L-15 and IL-2 biologic activity inhibitor | |
| JOP20230174A1 (en) | GITR inhibitors and how to use them |